After Wedbush and H.C. Wainwright gave Stemline Therapeutics (NASDAQ: STML) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics today. The company’s shares closed last Monday at $9.90.
According to TipRanks.com, Peaker is a 3-star analyst with an average return of 1.0% and a 42.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Pacira Pharmaceuticals, and Emergent Biosolutions.
Currently, the analyst consensus on Stemline Therapeutics is a Strong Buy with an average price target of $24.33, implying a 132.2% upside from current levels. In a report issued on November 25, Alliance Global Partners also initiated coverage with a Buy rating on the stock with a $21.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.22 and a one-year low of $7.82. Currently, Stemline Therapeutics has an average volume of 611.6K.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STML in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.
